Miami-based Orthodontix and Israel's Protalix have agreed to merge. Once the merger is complete a small group of investors, including Dr. Phillip Frost and Glenn Halpryn, who own a majority interest in Orthodontix, will invest $15 million in Protalix in exchange for 14 percent of the company. "We are excited by the breadth of Protalix's unique plant cell culture bioreactor platform, the quality of the management team and the prospects for the company's products and technology, particularly its lead product for the treatment of Gaucher Disease, which is progressing through the clinical development process," stated Dr. Phillip Frost.
- see the release on the merger